Astrazeneca | Patient Daily

Astrazeneca

Press release submission | Sep 16, 2018

ASTRAZENECA: US FDA approves LUMOXITI™ (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukemia

Marian Johns | Jan 17, 2018

FDA approves Lynparza as first PARP Inhibitor for treating metastatic breast cancer

Trending

Patient Daily | Mar 14, 2025

Doctor on weather-related pressure headaches: This could happen 'if you have an underlying chronic sinus disease'

Patient Daily | Mar 14, 2025

Founder of Medfluence Advisors on healthcare marketing: 'The patient journey is more complex than ever'

C.D. Marsden | Mar 14, 2025

Solidarity Health to Musk, RFK, Jr: ‘Enforce the CMS Hospital Price Transparency Rule’